ARF: A versatile DNA damage response ally at the crossroads of development and tumorigenesis

Frontiers in Genetics

Volumn 5, Issue JUL, 2014, Pages

  Kotsinas, Athanassios ^a   Papanagnou, Panagiota ^a   Evangelou, Konstantinos ^a   Trigas, George C ^a   Kostourou, Vassiliki ^b   Townsend, Paul ^c,d   Gorgoulis, Vassilis G ^a,c,d,e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Angiogenesis; ARF; ATM; Involution; Meiosis; Ocular development; Spermatogenesis; Vascular network

Indexed keywords

ALTERNATIVE READING FRAME; ATM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL MATURATION; DNA DAMAGE; GENOMIC INTEGRITY; HEREDITY; HUMAN; NONHUMAN; PROTEIN EXPRESSION; SPERMATOGENESIS;

EID: 84906275070     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2014.00236     Document Type: Article

References (43)

1. Barlow, C., Hirotsune, S., Paylor, R., Liyanage, M., Eckhaus, M., Collins, F.,et al. (1996). Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86, 159-171. doi: 10.1016/S0092-8674(00)80086-0
2. Barlow, C., Liyanage, M., Moens, P. B., Tarsounas, M., Nagashima, K., Brown, K.,et al. (1998). Atm deficiency results in severe meiotic disruption as early as leptonema of prophase I. Development 125, 4007-4017.
3. Bergers, G., and Benjamin, L. E. (2003). Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410. doi: 10.1038/nrc1093
4. Busch, S. E., Gurley, K. E., Moser, R. D., and Kemp, C. J. (2012). ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model. J. Pathol. 227, 298-305. doi: 10.1002/path.4024
5. Cooke, H. J., and Saunders, P. T. (2002). Mouse models of male infertility. Nat. Rev. Genet. 3, 790-801. doi: 10.1038/nrg911
6. Churchman, M. L., Roig, I., Jasin, M., Keeney, S., and Sherr, C. J. (2011). Expression of arf tumor suppressor in spermatogonia facilitates meiotic progression in male germ cells. PLoS Genet. 7:e1002157. doi: 10.1371/journal.pgen.1002157
7. Crinò, L., and Metro, G. (2014). Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur. Respir. Rev. 23, 79-91. doi: 10.1183/09059180.00008913
8. ARFconfers resistance to heat shock- and oxidative stress-mediated cell death by upregulating β-catenin. Int. J. Cancer 128, 1989-1995. doi: 10.1002/ijc.25510
9. ARFtumor suppressor. Genes Dev. 12, 2434-2442. doi: 10.1101/gad.12.15.2434
10. Eisen, T., Sternberg, C. N., Robert, C., Mulders, P., Pyle, L., Zbinden, S.,et al. (2012). Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J. Natl. Cancer Inst. 104, 93-113. doi: 10.1093/jnci/djr511
11. Elson, A., Wang, Y., Daugherty, C. J., Morton, C. C., Zhou, F., Campos-Torres, J.,et al. (1996). Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 93, 13084-13089. doi: 10.1073/pnas.93.23.13084
12. Fatyol, K., and Szalay, A. A. (2001). The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits HIF-1-mediated transcription. J. Biol. Chem. 276, 28421-28429. doi: 10.1074/jbc.M102847200
13. Ferrara, N., Hillan, K. J., Gerber, H. P., and Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400. doi: 10.1038/nrd1381
14. Freeman-Anderson, N. E., Zheng, Y., McCalla-Martin, A. C., Treanor, L. M., Zhao, Y. D., Garfin, P. M.,et al. (2009). Expression of the Arf tumor suppressor gene is controlled by Tgfbeta2 during development. Development 136, 2081-2089. doi: 10.1242/dev.033548
15. Golding, S. E., Rosenberg, E., Valerie, N., Hussaini, I., Frigerio, M., Cockcroft, X. F.,et al. (2009). Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 8, 2894-902. doi: 10.1158/1535-7163.MCT-09-0519
16. González-Navarro, H., Abu Nabah, Y. N., Vinué, A., Andrés-Manzano, M. J., Collado, M., Serrano, M.,et al. (2010). p19ARF deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J. Am. Coll. Cardiol. 55, 2258-2268. doi: 10.1016/j.jacc.2010.01.026
17. Gromley, A., Churchman, M. L., Zindy, F., and Sherr, C. J. (2009). Transient expression of the Arf tumor suppressor during male germ cell and eye development in Arf-Cre reporter mice. Proc. Natl. Acad. Sci. U.S.A. 106, 6285-6290. doi: 10.1073/pnas.0902310106
18. Inagaki, A., Schoenmakers, S., and Baarends, W. M. (2010). DNA double strand break repair, chromosome synapsis and transcriptional silencing in meiosis. Epigenetics 5, 255-266. doi: 10.4161/epi.5.4.11518
19. Kamijo, T., Bodner, S., van de Kamp, E., Randle, D. H., and Sherr, C. J. (1999). Tumor spectrum in ARF-deficient mice. Cancer Res. 59, 2217-2222.
20. Kawagishi, H., Nakamura, H., Maruyama, M., Mizutani, S., Sugimoto, K., Takagi, M.,et al. (2010). ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA. Cancer Res. 70, 4749-4758. doi: 10.1158/0008-5472.CAN-10-0368
21. Kerr, B. A., and Byzova, T. V. (2012). The dark side of the oxidative force in angiogenesis. Nat. Med. 18, 1184-1185. doi: 10.1038/nm.2881
22. Kotsinas, A., Papanagnou, P., Galanos, P., Schramek, D., Townsend, P., Penninger, J. M.,et al. (2014). MKK7 and ARF: new players in the DNA damage response scenery. Cell Cycle 13, 1227-1236. doi: 10.4161/cc.28654
23. Liontos, M., Pateras, I. S., Evangelou, K., and Gorgoulis, V. G. (2012). The tumor suppressor gene ARF as a sensor of oxidative stress. Curr. Mol. Med. 12, 704-715. doi: 10.2174/156652412800792633
24. Lowe, S. W., and Sherr, C. J. (2003). Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13, 77-83. doi: 10.1016/S0959-437X(02)00013-8
25. McKeller, R. N., Fowler, J. L., Cunningham, J. J., Warner, N., Smeyne, R. J., Zindy, F.,et al. (2002). The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc. Natl. Acad. Sci. U.S.A. 99, 3848-3853. doi: 10.1073/pnas.052484199
26. Palmero, I., Pantoja, C., and Serrano, M. (1999). p19ARF links the tumour suppressor p53 to Ras. Nature 395, 125-126. doi: 10.1038/25870
27. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. (1995). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-100. doi: 10.1016/0092-8674(95)90214-7
28. Randall, L. M., and Monk, B. J. (2010). Bevacizumab toxicities and their management in ovarian cancer. Gynecol. Oncol. 117, 497-504. doi: 10.1016/j.ygyno.2010.02.021
29. Saporita, A. J., Maggi, L. B. Jr., Apicelli, A. J., and Weber, J. D. (2007). Therapeutic targets in the ARF tumor suppressor pathway. Curr. Med. Chem. 14, 1815-1827. doi: 10.2174/092986707781058869
30. Sherr, C. J. (2006). Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6, 663-73. doi: 10.1038/nrc1954
31. Silva, R. L., Thornton, J. D., Martin, A. C., Rehg, J. E., Bertwistle, D., Zindy, F.,et al. (2005). Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye. EMBO J. 24, 2803-2814. doi: 10.1038/sj.emboj.7600751
32. Sugimoto, M., Kuo, M. L., Roussel, M. F., and Sherr, C. J. (2003). Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol. Cell. 11, 415-424. doi: 10.1016/S1097-2765(03)00057-1
33. Tago, K., Chiocca, S., and Sherr, C. J. (2005). Sumoylation induced by the Arf tumor suppressor: a p53-independent function. Proc. Natl. Acad. Sci. U.S.A. 102, 7689-7694. doi: 10.1073/pnas.0502978102
34. Takubo, K., Ohmura, M., Azuma, M., Nagamatsu, G., Yamada, W., Arai, F.,et al. (2008). Stem cell defects in ATM-deficient undifferentiated spermatogonia through DNA damage-induced cell-cycle arrest. Cell Stem Cell 2, 170-182. doi: 10.1016/j.stem.2007.10.023
35. -/- mice. Cell Cycle 4, 1316-1319. doi: 10.4161/cc.4.10.2109
36. Través, P. G., Luque, A., and Hortelano, S. (2012). Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflamm. 2012, 568783. doi: 10.1155/2012/568783
37. Tsantoulis, P. K., and Gorgoulis, V. G. (2005). Involvement of E2F transcription factor family in cancer. Eur. J. Cancer 41, 2403-2414. doi: 10.1016/j.ejca.2005.08.005
38. Arffacilitates the angiogenic switch and tumor initiation in a multi-stage cancer model via p53-dependent and independent mechanisms. PLoS ONE 5:e12454. doi: 10.1371/journal.pone.0012454
39. Velimezi, G., Liontos, M., Vougas, K., Roumeliotis, T., Bartkova, J., Sideridou, M.,et al. (2013). Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. Nat. Cell Biol. 15, 967-977. doi: 10.1038/ncb2795
40. ARFtumor suppressor. Genes Dev. 14, 2358-2365. doi: 10.1101/gad.827300
41. Xu, Y., Ashley, T., Brainerd, E. E., Bronson, R. T., Meyn, M. S., and Baltimore, D. (1996). Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10, 2411-2422. doi: 10.1101/gad.10.19.2411
42. Yi, Y., Shepard, A., Kittrell, F., Mulac-Jericevic, B., Medina, D., and Said, T. K. (2004). p19ARF determines the balance between normal cell proliferation rate and apoptosis during mammary gland development. Mol. Biol. Cell 15, 2302-2311. doi: 10.1091/mbc.E03-11-0785
43. Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J.,et al. (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12, 2424-2433. doi: 10.1101/gad.12.15.2424